Biolinq

Founded in 2012 and based in San Diego, Biolinq develops a wearable biosensor that uses an array of microscopic electrochemical sensors to measure glucose intradermally — just beneath the skin's surface rather than in deeper interstitial fluid. The device pairs a worn-on-the-forearm sensor with a color-coded indicator light that signals when glucose is in or out of range without requiring a phone. The company received FDA De Novo classification for a needle-free glucose monitor and closed a $100M Series C in April 2025 led by Alpha Wave Ventures, building on a $58M raise in April 2024 tied to its pivotal trial. It positions the product for the large population of people with type 2 diabetes who do not use insulin.